New international guidance supports its use from age four, signalling growing confidence in the treatment’s safety.
International dermatology experts have endorsed low-dose oral minoxidil for children as young as four, challenging longstanding concerns about using the antihypertensive drug to treat childhood hair loss.
The international consensus statement is the first detailed guidance on low-dose oral minoxidil for younger children and is an important shift in confidence around the treatment’s safety, says Melbourne dermatologist Professor Rodney Sinclair.
The consensus statement, published in JAMA Dermatology, supports the off-label treatment in children aged four to 12 years, including those with alopecia areata, androgenetic alopecia, telogen effluvium, and certain congenital hair disorders.
The recommendations represent a significant development for clinicians managing childhood hair loss, where treatment options have remained limited and evidence supporting oral minoxidil has largely been restricted to small retrospective studies and case series.
Professor Sinclair, who advised on the consensus statement, said the findings reflected growing confidence in the safety of a medication originally developed to treat hypertension.
“I think it’s actually really important because the whole history of oral minoxidil, people were thinking that this is an antihypertensive medication, it’s not something you should be using [for] something as trivial as hair loss,” he told Dermatology Republic.
“And it’s taken years for people to become comfortable with the safety.
“This is just a further extension of the comfort with the safety to show that there’s now expert consensus opinion that it is safe to use in paediatric hair disorders, because we do see a lot of paediatric hair disorders, including alopecia areata, where minoxidil is beneficial.”
Professor Sinclair said the statement was an important contribution to the growing evidence base supporting oral minoxidil in dermatology.
The international panel used a modified Delphi process involving 50 experts from nine countries, including Australia, the US, Canada, and the UK.
Participants were required to have treated at least 10 children younger than 12 years with low-dose oral minoxidil.
Across three survey rounds conducted between June 2025 and March 2026, the panel achieved consensus on 84 of 127 statements covering patient selection, indications, contraindications, dosing, monitoring, and treatment duration.
Related
There was unanimous agreement supporting low-dose oral minoxidil for hair follicle miniaturisation, including androgenetic alopecia, traction alopecia, and alopecia areata, as well as hair cycle abnormalities such as telogen effluvium and loose anagen syndrome.
The panel also supported its use for hair shaft disorders, with 84% agreement, and as an adjunctive treatment for selected scarring alopecias, with 98% agreement.
However, the experts emphasised that minoxidil would not restore follicles already destroyed by scarring.
The statement provided two approaches to paediatric dosing, including fixed doses based on body weight and an alternative starting dose of 0.01-0.02mg/kg/day.
Under the fixed-dose approach, children weighing less than 20kg may receive 0.25-0.625mg daily, those weighing 20-40kg may receive 1.25mg, and those above 40kg may receive 1.875mg.
Doses may be increased by 50-100% of the starting dose according to clinical response and tolerability, with reassessment every three to six months.
The panel also identified circumstances in which oral minoxidil may be preferable to topical treatment, particularly where there was difficulty applying topical formulations, poor tolerability, inadequate efficacy, diffuse hair loss, and sensory sensitivities.
Caregiver preference was another consideration, with 92% of experts supporting oral treatment when parents preferred it following shared decision-making.
The statement suggested routine baseline investigations and blood pressure monitoring may not be necessary in otherwise low-risk children.
However, the experts identified a history of pericardial effusion or tamponade and pheochromocytoma as contraindications. Additional precautions included hypotension, cardiac arrhythmias, congenital heart disease, renal or hepatic impairment, and concomitant medications with cardiovascular effects.
Specialist consultation was recommended when precautions or contraindications were identified or coordination of care was required.
The panel also recommended counselling families about adverse effects, particularly hypertrichosis, dizziness, abnormal heartbeat, peripheral oedema, headache, and facial swelling. Unexplained vision loss should prompt urgent ophthalmological assessment, the statement said.
Although experts agreed that routine blood pressure monitoring may be unnecessary in low-risk children, they emphasised the importance of individualised risk assessment and ongoing clinical review.
Visible improvement in hair growth was generally expected after at least three months, most commonly between three and 12 months.
Once clinically stable, children could be reviewed every six to 12 months, with earlier follow-up during treatment initiation, dose adjustments or adverse events.
The panel also supported long-term treatment for chronic hair disorders, noting that hair loss may recur after discontinuation.
However, the experts cautioned that the recommendations should not be interpreted as proof of clinical efficacy or long-term safety.
There are currently no randomised clinical trials evaluating the efficacy or long-term safety of low-dose oral minoxidil in children younger than 12 years.
The experts acknowledged that the Delphi methodology relied on expert opinion rather than prospective trial data and that selecting clinicians already experienced in prescribing the medication could introduce bias.
Consensus was also not achieved on treatment in children younger than four years, while uncertainties remained around long-term safety, including potential developmental and reproductive effects.
The researchers called for prospective paediatric studies to establish efficacy, refine dosing and better characterise long-term risks.
Nevertheless, Professor Sinclair, who is also editor of Dermatology Republic, said the statement provided clinicians with a practical framework for prescribing a treatment already gaining traction in paediatric dermatology.
He said the significance lay in the profession’s increasing willingness to consider oral minoxidil for younger patients with hair disorders, rather than dismissing it because of its origins as an antihypertensive.
“I think it is an important contribution,” he said.
